Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Weekly FDA Drug Pipeline Calendar (Dec 12 - Dec 17)

avatar
BioPharm Insight US wrote a column · Dec 12, 2022 10:20
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
$Amgen(AMGN.US)$ Inc. is in advanced talks to buy drug company $Horizon Therapeutics(HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
$ROCHESTER RESOURCES LTD(RCTFF.US)$Holding AG presented new data from a Phase 3 study showing that its Polivy antibody-drug can significantly reduce the risk of disease deterioration or death for people with untreated diffuse large B-cell lymphoma.
Danish biotechnology companies $NOVONESIS (NOVOZYMES) B UNSP ADR EACH REP 1 SER'B' DKK10(NVZMY.US)$and $CHR. HANSEN HOLDING A/S SPON ADS EACH REP 0.25 ORD SHS(CHYHY.US)$ said Monday they have agreed to merge, creating a biological solutions provider with combined annual revenue of around 3.5 billion euros ($3.69 billion).
BIGGEST MOVERS FROM THIS WEEK
$Ambrx Biopharma(AMAM.US)$ shares closed up higher this week after it released Phase 2 ACE Breast-03 study of ARX788 to treat HER2-positive mBC patients who are resistant or refractory to T-DM1. The data reported a 51.7% overall response rate (ORR) by RECIST v1.1 and a 100% disease control rate (DCR). Shares closed the week up 735% at $4.26.
$Pharvaris(PHVS.US)$ shares soared this week after it announced that its Phase 2 RAPIDe-1 trial of PHVS416 as a treatment for hereditary angioedema (HAE) attacks met its primary endpoint. Shares closed the week up 339% at $8.78.
$Summit Therapeutics(SMMT.US)$ entered into a licensing agreement with Akeso Inc. for the commercialization of ivonescimab (PD-1/VEGF). Akeso Inc will receive $500 million upfront with the deal totalling $5 billion including milestones. Shares closed the week up 400% at $3.90.
$Prometheus Biosciences(RXDX.US)$ had a busy week with the release of data from two PRA023 trials, the Phase 2 ARTEMIS-UC and Phase 2a APOLLO-CD trials. Both reported positive data sending the shares higher. Later in the week Prometheus
EVENTS TO WATCH
Tuesday, December 13, 2022
Advisory Committee $Cytokinetics(CYTK.US)$ Omecamtiv Mecarbil
4Q $NeuroOne Medical(NMTC.US)$ Earnings
Nov. Consumer Price Index 8:30 am ET

Wednesday, December 14, 2022
PDUFA $Zai Lab(ZLAB.US)$ Adagrasib for NSCLC
Friday, December 16, 2022
Initial Public Offering (IPO) for $Cadrenal Therapeutics(CVKD.US)$
Weekly FDA Drug Pipeline Calendar (Dec 12 - Dec 17)
Source: CNBC, BioPharmCatalyst, Benzinga
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
14
+0
2
Translate
Report
93K Views
Comment
Sign in to post a comment
We are the content provider of Moomoo Courses.
909Followers
8Following
1459Visitors
Follow